NDA 018925 · Exela Pharma
Verapamil Hydrochloride
Verapamil Hydrochloride · Intravenous
Last checked: Nov 20, 2026Latest source record: Nov 18, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1984
Mar 30, 1984
Approved uses
1
Original approval plus efficacy supplements
Registered trials
143
16 Phase 3, 13 recruiting
FAERS reports
4,312
3,916 serious, 958 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 26, 2024.
INDICATIONS & USAGE Verapamil is indicated for the treatment of supraventricular tachyarrhythmias, including: • Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White [WPW] and Lown-Ganong-Levine [LGL] syndromes). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver) should be attempted prior to Verapamil administration. • Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation, except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (Wolff-Parkinson-White [WPW] and Lown-Ganong-Levine [LGL] syndromes). In controlled studies in the U.S., about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous Verapamil hydrochloride. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutter and/or fibrillation with a fast ventricular rate respond with a decrease in heart rate of at least 20%. Conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after Verapamil hydrochloride and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. The effect of a single injection lasts for 30–60 minutes when conversion to sinus rhythm does not occur. Because a small fraction (<1.0%) of patients treated with Verapamil hydrochloride respond with life-threatening adverse responses (rapid ventricular rate in atrial flutter/fibrillation with an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole—see Contraindications and Warnings), the initial use of intravenous...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 30, 1984 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
- VERAPAMIL HYDROCHLORIDE · VERAPAMIL HYDROCHLORIDE 10MG/4ML (2.5MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
- VERAPAMIL HYDROCHLORIDE · VERAPAMIL HYDROCHLORIDE 5MG/2ML (2.5MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Verapamil" as an intervention, any sponsor and status, largest first.
- INVEST: INternational VErapamil SR Trandolapril STudyPivotal-lookingCompleted
University of FloridaAcademic, hospital or other
NCT00133692 · 22,000 participants · Start Sep 1997
Drug: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ); Atenolol/HCTZ/Trandolapril · For: Hypertension; Coronary Artery Disease
Sites: Gainesville, Florida
- Coronavirus (COVID-19) ACEi/ARB InvestigationPivotal-lookingSuspended
National University of Ireland, Galway, IrelandAcademic, hospital or other
NCT04330300 · 2,414 participants (planned) · Start Apr 30, 2020 · Primary completion Jul 31, 2021
Drug: Thiazide or Thiazide-like diuretics; Calcium Channel Blockers and 2 more · For: Hypertension; COVID-19
Sites: Galway, Ireland
- Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation TrialPivotal-lookingCompleted
Mayo ClinicAcademic, hospital or other
NCT00911508 · 2,204 participants · Start Nov 13, 2009 · Primary completion Dec 31, 2017
Drug: Rate or Rhythm Control Therapy · For: Atrial Fibrillation; Arrhythmia
Sites: Little Rock, Arkansas; Los Angeles, California; Sacramento, California · 118 sites in all
AbbottIndustry
NCT00233532 · 2,000 participants · Start Mar 2004 · Primary completion Jun 2005
Drug: Trandolapril · For: Hypertension
- A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)Pivotal-lookingCompleted
AbbottIndustry
NCT00235014 · 1,204 participants · Start Mar 1997 · Primary completion Jan 2006
Drug: trandolapril; trandolapril/verapamil and 2 more · For: Hypertension; Diabetes
- Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCIPivotal-lookingRecruiting
Medical University of GdanskAcademic, hospital or other
NCT04695106 · 1,194 participants (planned) · Start Oct 25, 2021 · Primary completion Jul 11, 2026
Drug: Ticagrelor; Dabigatran Etexilate and 2 more · For: Atrial Fibrillation; Antithrombotic Therapy; Acute Coronary Syndrome and 1 more
Sites: Gdansk, Poland
- Flecainide Safety in Patients With Coronary Artery Disease and Atrial FibrillationPivotal-lookingRecruiting
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
NCT07405671 · 988 participants (planned) · Start Sep 2026 · Primary completion Dec 2029
Drug: flecainide; Sotalol or Amiodarone · For: Atrial Fibrillation (AF); Coronary Artery Disease
Sites: Aalst, Belgium; Bonheiden, Belgium; Bruges, Belgium · 14 sites in all
- Amiodarone or Verapamil in COVID-19 Hospitalized Patients With SymptomsPivotal-lookingCompleted
Nicolaus Copernicus UniversityAcademic, hospital or other
NCT04351763 · 804 participants · Start May 20, 2020 · Primary completion May 25, 2021
Drug: Amiodarone; Verapamil · For: COVID-19
Sites: Bydgoszcz, Poland
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea357
- nausea353
- drug interaction316
- dizziness293
- hypotension287
- fatigue277
- diarrhoea271
- abdominal pain245
- vomiting244
- cough242
- headache238
- fall237
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 82 |
| 2005 | 130 |
| 2006 | 122 |
| 2007 | 58 |
| 2008 | 90 |
| 2009 | 53 |
| 2010 | 86 |
| 2011 | 79 |
| 2012 | 112 |
| 2013 | 61 |
| 2014 | 109 |
| 2015 | 160 |
| 2016 | 187 |
| 2017 | 187 |
| 2018 | 199 |
| 2019 | 217 |
| 2020 | 243 |
| 2021 | 273 |
| 2022 | 488 |
| 2023 | 407 |
| 2024 | 438 |
| 2025 | 331 |
| 2026 | 200 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study.
Millward MJ, Cantwell BM, Munro NC, et al. · Br J Cancer 1993 · Clinical Trial, Randomized Controlled Trial
- Role of P-glycoprotein inhibitors in children with drug-resistant epilepsy.
Elkhayat HA, Aly RH, Elagouza IA, et al. · Acta Neurol Scand 2017 · Randomized Controlled Trial
- Systematic literature review and Bayesian network meta-analysis of episodic cluster headache drugs.
Pompilio G, Migliore A, Integlia D · Eur Rev Med Pharmacol Sci 2021 · Network Meta-Analysis, Systematic Review
- Greater occipital nerve injection with methylprednisolone as transitional therapy in episodic cluster headache: Results from an RCT.
Brandt RB, Mulleners WM, Couturier E, et al. · Cephalalgia 2025 · Clinical Trial, Phase IV, Multicenter Study
- Intra-arterial nicardipine versus verapamil during transradial access coronary catheterization.
Patel K, Duckett M, Vidovich MI, et al. · Cardiovasc Revasc Med 2025 · Randomized Controlled Trial, Comparative Study
- Comparing intralesional triamcinolone and verapamil-triamcinolone injections in keloids: A single-blinded randomised clinical trial.
Haghani-Dogahe Z, Hadadi R, Esmailzadeh M, et al. · Int Wound J 2023 · Randomized Controlled Trial
Sponsor: Exela Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.